Literature DB >> 18366996

Challenges in developing drugs for the metabolic syndrome.

Glenn Matfin1.   

Abstract

Metabolic syndrome refers to a clustering of established and emerging cardiovascular disease (CVD) risk factors within a single individual. The established risk factors--such as obesity, diabetes, dyslipidemia, hypertension--and other emerging risk factors are closely related to central obesity (especially intra-abdominal adiposity). Insulin resistance is also an important factor in this syndrome's etiology. However, despite the potential use of having all the CVD risk factors under an umbrella diagnosis of metabolic syndrome, debate continues about the very existence of the metabolic syndrome. Despite the controversies, many existing therapies and new drugs in development are targeting the metabolic syndrome. To date, no drugs are approved specifically for treating the metabolic syndrome. This article discusses some of the challenges in developing therapies for the metabolic syndrome.

Entities:  

Mesh:

Year:  2008        PMID: 18366996     DOI: 10.1007/s11892-008-0007-0

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  27 in total

1.  Risk factors for coronary heart disease in diabetes.

Authors:  V A Fonseca
Journal:  Ann Intern Med       Date:  2000-07-18       Impact factor: 25.391

Review 2.  Clinical application of C-reactive protein for cardiovascular disease detection and prevention.

Authors:  Paul M Ridker
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

3.  The metabolic syndrome--a new worldwide definition.

Authors:  K George M M Alberti; Paul Zimmet; Jonathan Shaw
Journal:  Lancet       Date:  2005 Sep 24-30       Impact factor: 79.321

4.  The metabolic syndrome: time to reflect.

Authors:  K George M M Alberti; P Zimmet
Journal:  Curr Diab Rep       Date:  2006-08       Impact factor: 4.810

5.  Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD).

Authors:  Lars Rydén; Eberhard Standl; Małgorzata Bartnik; Greet Van den Berghe; John Betteridge; Menko-Jan de Boer; Francesco Cosentino; Bengt Jönsson; Markku Laakso; Klas Malmberg; Silvia Priori; Jan Ostergren; Jaakko Tuomilehto; Inga Thrainsdottir; Ilse Vanhorebeek; Marco Stramba-Badiale; Peter Lindgren; Qing Qiao; Silvia G Priori; Jean-Jacques Blanc; Andrzej Budaj; John Camm; Veronica Dean; Jaap Deckers; Kenneth Dickstein; John Lekakis; Keith McGregor; Marco Metra; João Morais; Ady Osterspey; Juan Tamargo; José Luis Zamorano; Jaap W Deckers; Michel Bertrand; Bernard Charbonnel; Erland Erdmann; Ele Ferrannini; Allan Flyvbjerg; Helmut Gohlke; Jose Ramon Gonzalez Juanatey; Ian Graham; Pedro Filipe Monteiro; Klaus Parhofer; Kalevi Pyörälä; Itamar Raz; Guntram Schernthaner; Massimo Volpe; David Wood
Journal:  Eur Heart J       Date:  2007-01       Impact factor: 29.983

Review 6.  Metabolic syndrome: a solution in search of a problem.

Authors:  Ele Ferrannini
Journal:  J Clin Endocrinol Metab       Date:  2007-02       Impact factor: 5.958

7.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

Authors:  Luc F Van Gaal; Aila M Rissanen; André J Scheen; Olivier Ziegler; Stephan Rössner
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

Review 8.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  Richard Kahn; John Buse; Ele Ferrannini; Michael Stern
Journal:  Diabetes Care       Date:  2005-09       Impact factor: 19.112

Review 9.  Postprandial dysmetabolism and cardiovascular disease in type 2 diabetes.

Authors:  M E Tushuizen; M Diamant; R J Heine
Journal:  Postgrad Med J       Date:  2005-01       Impact factor: 2.401

10.  A strategy to reduce cardiovascular disease by more than 80%.

Authors:  N J Wald; M R Law
Journal:  BMJ       Date:  2003-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.